Salta al contenuto principale
Passa alla visualizzazione normale.

MARIA ROSARIA VALERIO

Curriculum e ricerca

Pubblicazioni

Data Titolo Tipologia Scheda
2024 Correction to: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (npj Breast Cancer Articolo in rivista Vai
2023 Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients Articolo in rivista Vai
2023 Letter to the Editor: statistics and clinical perception of patients' reported outcomes for palbociclib and abemaciclib: a sliding doors story Lettera Vai
2023 Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study Articolo in rivista Vai
2023 Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (npj Breast Cancer Articolo in rivista Vai
2023 Outcomes of Sentinel Lymph Node Biopsy for Patients With Node-positive Breast Cancer Treated With Neoadjuvant Chemotherapy Articolo in rivista Vai
2023 A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy Articolo in rivista Vai
2023 Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer Articolo in rivista Vai
2023 Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data Articolo in rivista Vai
2022 A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer Articolo in rivista Vai
2022 Stereotactic Radiotherapy in Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review Articolo in rivista Vai
2021 Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety Articolo in rivista Vai
2021 A Case of Follicular Tumor of Uncertain Malignant Potential (FT-UMP) with Glomeruloid Features Showing Capsular Mucinous Degeneration Articolo in rivista Vai
2021 The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial Articolo in rivista Vai
2021 Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial Articolo in rivista Vai
2021 Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer Articolo in rivista Vai
2021 PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting Articolo in rivista Vai
2021 Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study Articolo in rivista Vai
2021 Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) Articolo in rivista Vai
2021 Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report Articolo in rivista Vai
2021 Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis Articolo in rivista Vai
2021 WhatsApp Messenger use in oncology: a narrative review on pros and contras of a flexible and practical, non-specific communication tool Articolo in rivista Vai
2021 Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer Articolo in rivista Vai
2020 Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence Articolo in rivista Vai
2020 Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World Articolo in rivista Vai
2020 Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study Articolo in rivista Vai
2020 NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience Articolo in rivista Vai
2020 Current Role of Intraoperative Frozen Section Examination of Sentinel Lymph Node in Early Breast Cancer Articolo in rivista Vai
2020 High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data Articolo in rivista Vai
2020 Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor Articolo in rivista Vai
2020 Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken Articolo in rivista Vai
2020 Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma? Articolo in rivista Vai
2020 Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis Articolo in rivista Vai
2020 Lapatinib activity in a patient with encephalic metastases from trastuzumab-resistant her-2 positive breast cancer Articolo in rivista Vai
2020 Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient Articolo in rivista Vai
2020 Gastric metastasis from breast cancer Articolo in rivista Vai
2020 Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study Articolo in rivista Vai
2020 Axillary Nodal Burden in Breast Cancer Patients With Pre-operative Fine Needle Aspiration-proven Positive Lymph Nodes Compared to Those With Positive Sentinel Nodes Articolo in rivista Vai
2019 Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success Review essay (rassegna critica) Vai
2019 Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study Articolo in rivista Vai
2019 Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated? Articolo in rivista Vai
2019 Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies Articolo in rivista Vai
2018 Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience Articolo in rivista Vai
2018 Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study Articolo in rivista Vai
2017 Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study Articolo in rivista Vai
2017 Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 Study Abstract in atti di convegno pubblicato in rivista Vai
2017 The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs) Abstract in atti di convegno pubblicato in rivista Vai
2017 Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy Articolo in rivista Vai
2017 Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study Abstract in atti di convegno pubblicato in rivista Vai
2015 Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer Articolo in rivista Vai
2012 Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma Articolo in rivista Vai
2012 Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: The G-Step trial Articolo in rivista Vai
2012 Adherence, compliance and persistence to oral antineoplastic therapy: A review focused on chemotherapeutic and biologic agents Articolo in rivista Vai
2011 Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes Articolo in rivista Vai
2011 Metastatic seeding of colon adenocarcinoma manifesting as synchronous breast and chest wall localization: report of a case. Articolo in rivista Vai
2011 Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer Articolo in rivista Vai
2011 Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA) Articolo in rivista Vai
2011 Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel Articolo in rivista Vai
2011 Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients Articolo in rivista Vai
2011 Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial Articolo in rivista Vai
2010 Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Articolo in rivista Vai
2010 RUOLO DELL’ECOCOLOR DOPPLER TISSUTALE NELLA VALUTAZIONE DELLA CARDIOTOSSICITÀ DA CHEMIOTERAPICI eedings Vai
2009 L'impiego del Tachosil in chirurgia epatica Articolo in rivista Vai
2007 Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Articolo in rivista Vai
2007 Alexithymia and copyng style in women going to visit in a breast cancer center eedings Vai
2007 Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study Articolo in rivista Vai
2007 Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Abstract in rivista Vai
2007 Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan Articolo in rivista Vai
2007 Alexithymia and coping style in women going to visit in a breast cancer center. eedings Vai
2006 Clinical presentation and treatment of gastrointestinal stromal tumors. Articolo in rivista Vai
2006 Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study Articolo in rivista Vai
2006 Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study Articolo in rivista Vai
2006 Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Articolo in rivista Vai
2006 A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma Articolo in rivista Vai
2006 Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers Articolo in rivista Vai
2006 Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. Articolo in rivista Vai
2006 Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Articolo in rivista Vai
2006 A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. Articolo in rivista Vai
2005 The prognostic role of TP53 mutations in advanced laryngeal squamous cell carcinoma (LSCC). eedings Vai
2005 The Use of Gemcitabine in heavily pretreted breast cancer patients eedings Vai
2005 TP53 Mutation in exon 5 and S-Phase Fraction but not Mutations in Ras gene family and DNA-ploidy are Indipendent prognostic indicators in Laryngeal Squamous Cell Carcinoma eedings Vai
2005 Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Articolo in rivista Vai
2005 The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers Articolo in rivista Vai
2004 Terapia di seconda linea del carcinoma gastrico avanzato con la combinazione Irinotecan (Cpt 11) + Mitomicina (MMc). Studio di fase II del Gruppo Oncologico dell’Italia Meridionale (prot. GOIM 2106) VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 eedings Vai
2004 Epirubicina (EPI ) e Docetaxel (DOC ) come chemioterapia primaria ( C P ) nel trattamento del carcinoma mammario localmente avanzato ( CMLA ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 eedings Vai
2004 TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome Articolo in rivista Vai
2004 Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation eedings Vai
2004 Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer eedings Vai
2004 Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 eedings Vai
2004 Topotecan compared with no terapy and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study Articolo in rivista Vai
2004 GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY Articolo in rivista Vai
2004 Mitoxantrone + Prednisone versus Taxotere + Prednisone nel trattamento del carcinoma prostatico ormonorefrattario (cpor ). Studio randomizzato di fase II del Gruppo Oncologico dell’Italia Meridionale (GOIM ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 eedings Vai
2002 p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospective study with a five-year follow-up Articolo in rivista Vai
2002 DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study Articolo in rivista Vai
2001 DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study Articolo in rivista Vai